A phase II trial of bendamustine, carboplatin, and dexamethasone for refractory or relapsed peripheral T-cell lymphoma (BENCART trial)

Author:

Park Byeong-Bae1ORCID,Kim Won Seog2ORCID,Suh Cheolwon3ORCID,Hong Jung Yong3ORCID,Yang Deok-Hwan4ORCID,Lee Won Sik5ORCID,Do Young Rok6ORCID,Koh Young Il7ORCID,Won Jong-Ho8ORCID,Kim Min Kyoung9ORCID,Jo Jae-Cheol10ORCID,Hyun Shin Young11ORCID,Kim Jeong-A12ORCID,Oh Young Ha13ORCID,Lee Seung-Sook14ORCID

Affiliation:

1. Department of Internal Medicine, Division of Hematology/Oncology, Hanyang University College of Medicine, Seoul, Korea;

2. Department of Medicine, Division of Hematology/Oncology, Samsung Medical Center, Sungkyunkwan, University School of Medicine, Seoul, Korea;

3. Department of Oncology, Asan Medical Center, College of Medicine, University of Ulsan, Seoul, Korea;

4. Department of Hemato-Oncology, Chonnam National University Hwasun Hospital, Gwangju, Korea;

5. Department of Internal Medicine, Division of Hematology, Inje University Busan Paik Hospital, Busan, Korea;

6. Department of Medicine, Division of Hematology-Oncology, Dongsan Medical Center, Keimyung University School of Medicine, Daegu, South Korea;

7. Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea;

8. Department of Internal Medicine, Soon Chun Hyang University, Seoul, South Korea;

9. Department of Medicine, Yeungnam University College of Medicine, Daegu, Korea;

10. Department of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea;

11. Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea;

12. Department of Internal Medicine, Division of Hematology, St. Vincent’s Hospital, Catholic University of Korea College of Medicine, Suwon, Korea;

13. Department of Pathology, Hanyang University College of Medicine, Seoul, Korea;

14. Department of Pathology, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul, Korea

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3